Oral anticoagulants (NOAC and VKA) in chronic thromboembolic pulmonary hypertension
Research output: Contribution to journal › Research article › Contributed › peer-review
Contributors
Abstract
EXPERT was an international, multicenter, prospective, uncontrolled, non-interventional cohort study in patients with pulmonary hypertension treated with riociguat. Patients were followed for 1-4 years, and the primary outcomes were adverse events (AEs) and serious AEs (SAEs), including embolic/thrombotic and hemorrhagic events. Here we report data on patients with chronic thromboembolic pulmonary hypertension (CTEPH) receiving a vitamin K antagonist (VKA; n = 683) or a non-vitamin K antagonist oral anticoagulant (NOAC; n = 198) at baseline. AEs and SAEs were reported in 438 patients (64.1%) and 257 patients (37.6%), respectively, in the VKA group, and in 135 patients (68.2%) and 74 patients (37.4%) in the NOAC group. Exposure-adjusted hemorrhagic event rates were similar in the two groups, while exposure-adjusted embolic and/or thrombotic event rates were higher in the NOAC group, although the numbers of events were small. Further studies are required to determine the long-term effects of anticoagulation strategies in CTEPH.
Details
Original language | English |
---|---|
Pages (from-to) | 716-721 |
Number of pages | 6 |
Journal | Journal of Heart and Lung Transplantation |
Volume | 41 |
Issue number | 6 |
Publication status | Published - Jun 2022 |
Peer-reviewed | Yes |
External IDs
Scopus | 85126520056 |
---|
Keywords
Keywords
- chronic thromboembolic pulmonary hypertension, drug safety, non-vitamin K antagonist oral anticoagulants, riociguat, vitamin K antagonists